Business Wire: Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain ...
Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential ...
Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain ...
Nasdaq: Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology ...
Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology ...
Monthly Prescribing Reference: Gene Expression Profile Test IDs Patients Who Can Skip SLNB in Melanoma
Across primary sites, histological subtypes, and mitotic count categories, clinicopathological factors and gene-expression profile results were consistent for discriminating SLN positivity rates.
Gene Expression Profile Test IDs Patients Who Can Skip SLNB in Melanoma
ascopubs.org: The 31-gene expression profile as a guide to better risk-aligned care decisions for patients with stage I–III cutaneous melanoma: An NCI-SEER analysis.
The 31-gene expression profile as a guide to better risk-aligned care decisions for patients with stage I–III cutaneous melanoma: An NCI-SEER analysis.
TMCnet: Rgenta Therapeutics Announces Two Oral Presentations Highlighting Proprietary RSwitch Technology at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting
RSwitch is a proprietary regulatable gene therapy system that enables oral, small molecule drug control of transgene levels in gene and cell therapy applications. RSwitch encodes a "dimmer" switch ...